Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set

Lilah Besser, Walter Kukull, David S Knopman, Helena Chui, Douglas Galasko, Sandra Weintraub, Gregory Jicha, Cynthia Carlsson, Jeffrey Burns, Joseph Quinn, Robert A Sweet, Katya Rascovsky, Merilee Teylan, Duane Beekly, George Thomas, Mark Bollenbeck, Sarah Monsell, Charles Mock, Xiao Hua Zhou, Nicole Thomas, Elizabeth Robichaud, Margaret Dean, Janene Hubbard, Mary Jacka, Kristen Schwabe-Fry, Joylee Wu, Creighton Phelps, John C Morris, Neuropsychology Work Group, Directors, and Clinical Core leaders of the National Institute on Aging-funded US Alzheimer’s Disease Centers, Lilah Besser, Walter Kukull, David S Knopman, Helena Chui, Douglas Galasko, Sandra Weintraub, Gregory Jicha, Cynthia Carlsson, Jeffrey Burns, Joseph Quinn, Robert A Sweet, Katya Rascovsky, Merilee Teylan, Duane Beekly, George Thomas, Mark Bollenbeck, Sarah Monsell, Charles Mock, Xiao Hua Zhou, Nicole Thomas, Elizabeth Robichaud, Margaret Dean, Janene Hubbard, Mary Jacka, Kristen Schwabe-Fry, Joylee Wu, Creighton Phelps, John C Morris, Neuropsychology Work Group, Directors, and Clinical Core leaders of the National Institute on Aging-funded US Alzheimer’s Disease Centers

Abstract

Introduction: In 2015, the US Alzheimer's Disease Centers (ADC) implemented Version 3 of the Uniform Data Set (UDS). This paper describes the history of Version 3 development and the UDS data that are freely available to researchers.

Methods: UDS Version 3 was developed after years of coordination between the National Institute on Aging-appointed Clinical Task Force (CTF), clinicians from ∼30 ADCs, and the National Alzheimer's Coordinating Center (NACC). The CTF recognized the need for updates to align with the state of the science in dementia research, while being flexible to the diverse needs and diseases studied at the ADCs. Version 3 also developed a nonproprietary neuropsychological battery.

Results: This paper focuses on the substantial Version 3 changes to the UDS forms related to clinical diagnosis and characterization of clinical symptoms to match updated consensus-based diagnostic criteria. Between March 2015 and March 2018, 4820 participants were enrolled using UDS Version 3. Longitudinal data were available for 25,337 of the 37,568 total participants using all UDS versions.

Discussion: The results from utilization of the UDS highlight the possibility for numerous research institutions to successfully collaborate, produce, and use standardized data collection instruments for over a decade.

References

    1. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210–216.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
    1. Weintraub S, Besser L, Dodge HH, et al. Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord. 2018;32:10–17.
    1. Monsell SE, Dodge HH, Zhou XH, et al. Results from the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study. Alzheimer Dis Assoc Disord. 2016;30:134–139.
    1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–292.
    1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–279.
    1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269.
    1. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(pt 9):2456–2477.
    1. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
    1. National Alzheimer’s Coordinating Center. NACC Uniform Data Set Data Element Dictionary For Initial Visit Packet. 2015. Available at: . Accessed April 15, 2018.
    1. National Alzheimer’s Coordinating Center. NACC Uniform Data Set Coding Guidebook For Initial Visit Packet. 2015. Available at: . Accessed April 14, 2018.
    1. National Alzheimer’s Coordinating Center. NACC Uniform Data Set Instructions for the Neuropsychological Battery (Form C2). 2015. Available at: . Accessed April 14, 2018.
    1. Besser LM, Kukull WA, Teylan MA, et al. The revised National Alzheimer’s Coordinating Center’s Neuropathology Form—available data and new analyses. J Neuropathol Exp Neurol. 2018;77:717–726.
    1. Boise L, Hinton L, Rosen HJ, et al. Willingness to be a brain donor: a survey of research volunteers from 4 racial/ethnic groups. Alzheimer Dis Assoc Disord. 2017;31:135–140.
    1. Brenowitz WD, Hubbard RA, Keene CD, et al. Mixed neuropathologies and associations with domain-specific cognitive decline. Neurology. 2017;89:1773–1781.
    1. Agogo GRC, Gnjidic D, Moga D, et al. Longitudinal associations between different dementia diagnoses and medication. Int Psychogeriatr. 2018;18:1–11.
    1. Burke SL, Hu T, Fava NM, et al. Sex differences in the development of mild cognitive impairment and probable Alzheimer’s disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging. 2018:1–25.
    1. Burke SL, Maramaldi P, Cadet T, et al. Decreasing hazards of Alzheimer’s disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry. 2018;33:200–211.
    1. Cleary EG, Cifuentes M, Grinstein G, et al. Association of low-level ozone with cognitive decline in older adults. J Alzheimers Dis. 2018;61:67–78.
    1. Davis M, O’Connell T, Johnson S, et al. Estimating Alzheimer’s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr Alzheimer Res. 2018;15:777–788.
    1. de Leon MJ, Pirraglia E, Osorio RS, et al. The nonlinear relationship between cerebrospinal fluid Abeta42 and tau in preclinical Alzheimer’s disease. PLoS One. 2018;13:e0191240.
    1. Kaur A, Edland SD, Peavy GM. The MoCA-Memory Index Score: an efficient alternative to paragraph recall for the detection of amnestic mild cognitive impairment. Alzheimer Dis Assoc Disord. 2018;32:120–124.
    1. Kirson NY, Scott Andrews J, Desai U, et al. Patient characteristics and outcomes associated with receiving an earlier versus later diagnosis of probable Alzheimer’s disease. J Alzheimers Dis. 2018;61:295–307.
    1. Lin M, Gong P, Yang T, et al. Big data analytical approaches to the NACC Dataset: aiding preclinical trial enrichment. Alzheimer Dis Assoc Disord. 2018;32:18–27.
    1. Mitchell JA, Cadet T, Burke S, et al. The paradoxical impact of companionship on the mental health of older African American men. J Gerontol B Psychol Sci Soc Sci. 2018;73:230–239.
    1. Qian W, Fischer CE, Schweizer TA, et al. Association between psychosis phenotype and APOE genotype on the clinical profiles of Alzheimer’s disease. Curr Alzheimer Res. 2018;15:187–194.
    1. Ramsey CM, Gnjidic D, Agogo GO, et al. Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y). 2018;4:1–10.
    1. Schaffert J, LoBue C, White CL, et al. Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer’s disease. Neuropsychology. 2018;32:410–416.
    1. Stipho F, Jackson R, Sabbagh MN. Pathologically confirmed Alzheimer’s disease in APOE varepsilon2 homozygotes is rare but does occur. J Alzheimers Dis. 2018;62:1527–1530.
    1. Ting SKS, Foo H, Chia PS, et al. Dyslexic characteristics of Chinese-speaking semantic variant of primary progressive aphasia. J Neuropsychiatry Clin Neurosci. 2018;30:31–37.
    1. Tse KH, Cheng A, Ma F, et al. DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer’s disease and dementia. Alzheimers Dement. 2018;14:664–679.
    1. Weintraub S, Besser L, Dodge H, et al. Version 3 of the Alzheimer’s Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set. Alzheimer Dis Assoc Disord. 2018;32:10–17.
    1. National Alzheimer’s Coordinating Center. NACC Uniform Data Set Researchers Data Dictionary. 2015. Available at: . Accessed April 15, 2018.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi